抗血栓治疗对临床稳定型新冠门诊患者临床结局的影响:ACTIV-4B随机临床试验
ACTIV-4B试验计划纳入7000例症状性但临床稳定的新冠门诊患者,因事件率低于预期提前终止,实际随机657例。在558例启动治疗者中,阿司匹林、预防剂量阿哌沙班、治疗剂量阿哌沙班与安慰剂的主要复合终点发生率无显著差异,出血事件均非严重。
要点
- 症状性稳定新冠门诊患者中,阿司匹林或阿哌沙班未降低主要复合终点发生率。
- 治疗剂量阿哌沙班出血风险差异为6.9%(95%CI 1.4%至12.9%),但无严重出血。
- 试验因事件率低提前终止,仅入组计划的9%,结论需谨慎解读。
核心结论
- 在症状性临床稳定的新冠门诊患者中,与安慰剂相比,阿司匹林或阿哌沙班治疗未降低复合临床结局发生率。
- 试验因事件率低于预期在入组9%时提前终止。
研究设计与样本
- ACTIV-4B为最小接触、适应性、随机、双盲、安慰剂对照试验,计划纳入7000例症状性但临床稳定的新冠门诊患者。
- 实际在52个美国站点随机657例,中位年龄54岁(IQR 46-59),59%为女性。
- 随机前要求血小板计数大于100 000/mm3且估算肾小球滤过率大于30 mL/min/1.73 m2。
主要发现
- 在558例启动治疗者中,主要复合终点发生:阿司匹林组1例(0.7%)、2.5 mg阿哌沙班组1例(0.7%)、5 mg阿哌沙班组2例(1.4%)、安慰剂组1例(0.7%)。
- 与安慰剂相比的主要终点风险差:阿司匹林组0.0%(95%CI无法计算)、2.5 mg阿哌沙班组0.7%(95%CI -2.1%至4.1%)、5 mg阿哌沙班组1.4%(95%CI -1.5%至5.0%)。
- 与安慰剂相比的出血事件风险差:阿司匹林组2.0%(95%CI -2.7%至6.8%)、预防剂量阿哌沙班组4.5%(95%CI -0.7%至10.2%)、治疗剂量阿哌沙班组6.9%(95%CI 1.4%至12.9%),均非严重出血。
- 纳入所有随机患者的结果相似。
关键数值与推荐
- 随机分组比例为1:1:1:1,分别接受阿司匹林81 mg每日一次(n=164)、预防剂量阿哌沙班2.5 mg每日两次(n=165)、治疗剂量阿哌沙班5 mg每日两次(n=164)或安慰剂(n=164),疗程45天。
- 主要终点为全因死亡、症状性静脉或动脉血栓栓塞、心肌梗死、卒中或心血管/肺部原因住院的复合终点。
- 从诊断到随机中位时间7天,从随机到启动治疗中位时间3天。
临床怎么用
- 对于症状性但临床稳定的新冠门诊患者,不应常规使用阿司匹林或阿哌沙班以预防不良心肺结局。
- 治疗剂量阿哌沙班与安慰剂相比出血风险差异有统计学意义,但均为非严重出血,临床决策需个体化权衡。
局限性
- 试验因事件率低于预期提前终止,仅随机657例(计划的9%),统计效能不足。
- 主要分析限于启动治疗者(558例),可能引入选择偏倚。
- 事件数少,风险差异置信区间宽,尤其阿司匹林组95%CI无法计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy, although the risks and benefits of this intervention among outpatients with COVID-19 have not been established. OBJECTIVE: To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable outpatients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ACTIV-4B Outpatient Thrombosis Prevention Trial was designed as a minimal-contact, adaptive, randomized, double-blind, placebo-controlled trial to compare anticoagulant and antiplatelet therapy among 7000 symptomatic but clinically stable outpatients with COVID-19. The trial was conducted at 52 US sites between September 2020 and June 2021; final follow-up was August 5, 2021. Prior to initiating treatment, participants were required to have platelet count greater than 100 000/mm3 and estimated glomerular filtration rate greater than 30 mL/min/1.73 m2. INTERVENTIONS: Random allocation in a 1:1:1:1 ratio to aspirin (81 mg orally once daily; n = 164), prophylactic-dose apixaban (2.5 mg orally twice daily; n = 165), therapeutic-dose apixaban (5 mg orally twice daily; n = 164), or placebo (n = 164) for 45 days. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of all-cause mortality, symptomatic venous or arterial thromboembolism, myocardial infarction, stroke, or hospitalization for cardiovascular or pulmonary cause. The primary analyses for efficacy and bleeding events were limited to participants who took at least 1 dose of trial medication. RESULTS: On June 18, 2021, the trial data and safety monitoring board recommended early termination because of lower than anticipated event rates; at that time, 657 symptomatic outpatients with COVID-19 had been randomized (median age, 54 years [IQR, 46-59]; 59% women). The median times from diagnosis to randomization and from randomization to initiation of study treatment were 7 days and 3 days, respectively. Twenty-two randomized participants (3.3%) were hospitalized for COVID-19 prior to initiating treatment. Among the 558 patients who initiated treatment, the adjudicated primary composite end point occurred in 1 patient (0.7%) in the aspirin group, 1 patient (0.7%) in the 2.5-mg apixaban group, 2 patients (1.4%) in the 5-mg apixaban group, and 1 patient (0.7%) in the placebo group. The risk differences compared with placebo for the primary end point were 0.0% (95% CI not calculable) in the aspirin group, 0.7% (95% CI, -2.1% to 4.1%) in the 2.5-mg apixaban group, and 1.4% (95% CI, -1.5% to 5.0%) in the 5-mg apixaban group. Risk differences compared with placebo for bleeding events were 2.0% (95% CI, -2.7% to 6.8%), 4.5% (95% CI, -0.7% to 10.2%), and 6.9% (95% CI, 1.4% to 12.9%) among participants who initiated therapy in the aspirin, prophylactic apixaban, and therapeutic apixaban groups, respectively, although none were major. Findings inclusive of all randomized patients were similar. CONCLUSIONS AND RELEVANCE: Among symptomatic clinically stable outpatients with COVID-19, treatment with aspirin or apixaban compared with placebo did not reduce the rate of a composite clinical outcome. However, the study was terminated after enrollment of 9% of participants because of an event rate lower than anticipated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04498273.
引用
- Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. 2021. PMID: 34633405. doi:10.1001/jama.2021.17272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。